Trade Report: Today, Essex Investment Management Co. LLC Sold shares of Neurocrine Biosciences Inc. (NBIX)

Today, Essex Investment Management Co. LLC Sold shares of Neurocrine Biosciences Inc. (NBIX)

Essex Investment Management Co. LLC reduced its position in shares of Neurocrine Biosciences Inc. (NASDAQ:NBIX) by 9.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,127 shares of the company’s stock after selling 1,319 shares during the period. Essex Investment Management Co. LLC’s holdings in Neurocrine Biosciences were worth $597,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in NBIX. Capital Fund Management S.A. increased its stake in shares of Neurocrine Biosciences by 817.0% in the second quarter. Capital Fund Management S.A. now owns 77,121 shares of the company’s stock worth $3,505,000 after buying an additional 68,711 shares in the last quarter. Alps Advisors Inc. increased its stake in shares of Neurocrine Biosciences by 25.2% in the second quarter. Alps Advisors Inc. now owns 121,734 shares of the company’s stock worth $5,533,000 after buying an additional 24,508 shares in the last quarter. GW&K Investment Management LLC increased its stake in shares of Neurocrine Biosciences by 27.6% in the second quarter. GW&K Investment Management LLC now owns 85,588 shares of the company’s stock worth $3,890,000 after buying an additional 18,488 shares in the last quarter. American Century Companies Inc. increased its stake in shares of Neurocrine Biosciences by 890.6% in the second quarter. American Century Companies Inc. now owns 821,527 shares of the company’s stock worth $37,338,000 after buying an additional 738,598 shares in the last quarter. Finally, Moody Aldrich Partners LLC increased its stake in shares of Neurocrine Biosciences by 214.8% in the second quarter. Moody Aldrich Partners LLC now owns 30,960 shares of the company’s stock worth $1,407,000 after buying an additional 21,125 shares in the last quarter. 96.70% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Inc. (NASDAQ:NBIX) traded down 7.20% during mid-day trading on Thursday, reaching $47.57. 1,379,352 shares of the company traded hands. The firm’s market capitalization is $4.13 billion. The company’s 50 day moving average price is $50.98 and its 200 day moving average price is $47.34. Neurocrine Biosciences Inc. has a 12-month low of $31.25 and a 12-month high of $58.46.

A number of equities research analysts recently weighed in on the stock. Leerink Swann assumed coverage on shares of Neurocrine Biosciences in a research note on Tuesday. They issued an “outperform” rating and a $70.00 target price on the stock. BMO Capital Markets reissued an “outperform” rating and set a $66.00 price target on shares of Neurocrine Biosciences in a research note on Friday, September 23rd. Jefferies Group reissued a “buy” rating and set a $61.00 price target on shares of Neurocrine Biosciences in a research note on Friday, September 23rd. Piper Jaffray Cos. reissued an “overweight” rating and set a $96.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, September 22nd. Finally, Robert W. Baird reissued an “outperform” rating and set a $66.00 price target on shares of Neurocrine Biosciences in a research note on Tuesday, August 30th. One research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the stock. Neurocrine Biosciences has an average rating of “Buy” and a consensus target price of $65.50.

In other Neurocrine Biosciences news, insider Malcolm Lloyd-Smith sold 9,000 shares of the stock in a transaction on Thursday, September 1st. The stock was sold at an average price of $50.00, for a total value of $450,000.00. Following the sale, the insider now owns 9,000 shares in the company, valued at $450,000. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Corinne H. Nevinny sold 5,000 shares of the stock in a transaction on Monday, August 8th. The stock was sold at an average price of $48.54, for a total value of $242,700.00. Following the completion of the sale, the director now owns 25,555 shares in the company, valued at approximately $1,240,439.70. The disclosure for this sale can be found here. Corporate insiders own 4.80% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders.

Related posts

Leave a Comment